BrainsWay says pilot study shows 83.3% response rate for Deep TMS in depression with early-stage Alzheimer’s

BrainsWay said peer-reviewed pilot-study results already published on Sept. 8, 2026 showed an 83.3% response rate for Deep TMS in depression with early-stage Alzheimer’s.

Patients showed meaningful improvement in depressive symptoms, with many reaching remission, supporting further clinical development in this difficult-to-treat group.

Researchers also reported brain-activity changes consistent with improved network function, adding biological support to the clinical signal.

Deep TMS is not FDA-cleared for Alzheimer’s disease, placing any expansion into that indication behind additional controlled trials.